Evidence map›Paper›PMID 30130388›Full record

ArticleACS chemical biology2018

Evaluation of APOBEC3B Recognition Motifs by NMR Reveals Preferred Substrates.

Manjuan Liu, Aurélie Mallinger, Marcello Tortorici, Yvette Newbatt, Meirion Richards, Amin Mirza, Rob L M van Montfort, Rosemary Burke, Julian Blagg, Teresa Kaserer

Open access · hybridAbstract readLetter
In one paragraph

Article in ACS chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A.bioRxiv : the preprint server for biology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Manjuan LiuCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.
Aurélie MallingerCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.
Marcello TortoriciCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.
Yvette NewbattCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.
Meirion RichardsCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.
Amin MirzaCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.
Rob L M van MontfortCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.
Rosemary BurkeCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.
Julian BlaggCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.ORCID 0000-0002-7409-0323
Teresa KasererCancer Research UK Cancer Therapeutics Unit , The Institute of Cancer Research , London SM2 5NG , U.K.
Institute of Cancer Research · GB

Funding

Cancer Research UK 11566Cancer Research UK 22897Cancer Research UK C1362/A20263Cancer Research UK C309/A11566
6 · The paper itself

Abstract

APOBEC3B (A3B) deamination activity on ssDNA is considered a contributing factor to tumor heterogeneity and drug resistance in a number of human cancers. Despite its clinical impact, little is known about A3B ssDNA substrate preference. We have used nuclear magnetic resonance to monitor the catalytic turnover of A3B substrates in real-time. This study reports preferred nucleotide sequences for A3B substrates, including optimized 4-mer oligonucleotides, and reveals a breadth of substrate recognition that includes DNA sequences known to be mutated in drug-resistant cancer clones. Our results are consistent with available clinical and structural data and may inform the design of substrate-based A3B inhibitors.

Indexed as

Cytidine DeaminaseDNA, Single-StrandedHumansMinor Histocompatibility AntigensModels, MolecularNuclear Magnetic Resonance, BiomolecularNucleotidesSubstrate SpecificityAPOBEC3B protein, humanCytidine DeaminaseDNA, Single-StrandedMinor Histocompatibility AntigensNucleotides

Identifiers

PMID30130388
PMCPMC6430498
OpenAlexW2888007567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.